From June 16 to 18, 2026, the 24th Convention on Pharmaceutical Ingredients China (CPHI China 2026) was held at the Shanghai New International Expo Center. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. made its debut at Booth E3A21. In collaboration with Grand Life Sciences (Qingdao) Co., Ltd., Grand Life Sciences (Liaoning) Co., Ltd., and Grand Medical Nutrition Sciences (Wuhan) Co., Ltd., it showcased Grand Life Sciences Group's industrial layout and innovative achievements in the fields of blood products, probiotics, medical nutrition, and perioperative care.

As an influential global pharmaceutical exhibition, CPHI China gathered over 3,600 high-quality exhibitors and 100,000 visitors worldwide, covering the entire industry chain including pharmaceutical raw materials, natural products, biotechnology, pharmaceutical excipients, formulations, pharmaceutical outsourcing services, pharmaceutical machinery and packaging equipment, packaging and drug delivery systems, and laboratory instruments and equipment.

Focusing on Core Products to Demonstrate Full Industrial Chain Strength in Blood Products

As a leading enterprise in China's blood product industry, Grand Shuyang Life Sciences (Chengdu) Co., Ltd. has participated in the CPHI exhibition for consecutive years and demonstrated the outstanding capabilities of Chinese blood product companies to the global market. Leveraging a specialized plasma resource management system, mature and stable manufacturing processes, a rigorous quality management system, and continuous improvement in R&D innovation, Grand Shuyang has established comprehensive capabilities across the full industry chain, covering plasma collection, product R&D, large-scale manufacturing, quality control, and international registration and market expansion.

The Company showcased its core blood products, including human albumin, intravenous immunoglobulin, human coagulation factor, human fibrinogen, and specific immunoglobulins, attracting professional visitors from multiple countries across Asia-Pacific, the Middle East, Africa, and Latin America. These visitors engaged in in-depth discussions with the Company's team on topics such as blood product supply, international registration, technical cooperation, market access, and long-term commercial partnerships.

Tailoring the presentation to diverse clinical needs, regulatory standards, and market characteristics across countries and regions, the Grand Shuyang team comprehensively outlined the Company's product pipeline, quality system, production capabilities, and international development strategy to clients. The Company's professional expertise in blood products, stable supply capabilities, and continued progress in international registrations have gained considerable attention and recognition from numerous clients and industry partners.

Joining Forces with Grand Life Sciences (Qingdao) to Connect with Global Cooperation Resources

At this exhibition, Grand Shuyang fully leveraged the Group's global industrial presence and resource integration strengths, and for the first time invited Grand Life Sciences (Qingdao) Co., Ltd. to co-exhibit. By sharing the exhibition platform, customer networks, and brand influence, the collaboration further demonstrated the synergistic and complementary industrial ecosystem across multiple business segments of Grand Life Sciences Group. During the exhibition, the teams worked closely together to receive clients and partners from various countries and regions worldwide, and engaged in in-depth discussions with multiple domestic and international companies on potential cooperation models.

Going forward, the Company will enhance synergies and collaboration with various business segments of the Group to promote resource sharing, complementary strengths, and integrated development in fields such as blood products, biopharmaceuticals, and microbiome health, thereby providing global customers with higher-quality, more diverse, and more specialized products and services.